Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-drug conjugates - Bayer HealthCare

Drug Profile

Research programme: antibody-drug conjugates - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates; Anti-C4.4a-ADC; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Antibody-Eg5 inhibitor conjugates; Antibody-KIF11 inhibitor conjugates; Antibody-kinesin spindle protein inhibitor conjugates; Antibody-KSP inhibitor conjugates; FGFR2-ADC

Latest Information Update: 28 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Seattle Genetics
  • Class Antibodies; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 02 Sep 2016 The programme is still under preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top